These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 25848215)
21. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis. Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054 [TBL] [Abstract][Full Text] [Related]
22. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876 [TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219 [TBL] [Abstract][Full Text] [Related]
24. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394 [TBL] [Abstract][Full Text] [Related]
25. DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients. Liu Y; Zhou ZT; He QB; Jiang WW Med Oncol; 2012 Jun; 29(2):729-33. PubMed ID: 21516484 [TBL] [Abstract][Full Text] [Related]
26. Differential hypermethylation of death-associated protein kinase promoter in central neurocytoma and oligodendroglioma. Chung CL; Tsai HP; Tsai CY; Chen WT; Lieu AS; Wang CJ; Sheehan J; Chai CY; Kwan AL Biomed Res Int; 2014; 2014():506458. PubMed ID: 24877104 [TBL] [Abstract][Full Text] [Related]
27. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer. Katayama H; Hiraki A; Fujiwara K; Matsuo K; Maeda T; Chikamori K; Kishino D; Tajima K; Ueoka H; Aoe K Asian Pac J Cancer Prev; 2007; 8(2):221-4. PubMed ID: 17696735 [TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681 [TBL] [Abstract][Full Text] [Related]
29. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757 [TBL] [Abstract][Full Text] [Related]
30. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis. Xu L; Lan H; Su Y; Li J; Wan J Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616 [TBL] [Abstract][Full Text] [Related]
31. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Divine KK; Pulling LC; Marron-Terada PG; Liechty KC; Kang T; Schwartz AG; Bocklage TJ; Coons TA; Gilliland FD; Belinsky SA Int J Cancer; 2005 Apr; 114(3):400-5. PubMed ID: 15578700 [TBL] [Abstract][Full Text] [Related]
32. Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Leung RC; Liu SS; Chan KY; Tam KF; Chan KL; Wong LC; Ngan HY Oncol Rep; 2008 May; 19(5):1339-45. PubMed ID: 18425396 [TBL] [Abstract][Full Text] [Related]
33. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478 [TBL] [Abstract][Full Text] [Related]
34. Transcription control of DAPK. Benderska N; Schneider-Stock R Apoptosis; 2014 Feb; 19(2):298-305. PubMed ID: 24217921 [TBL] [Abstract][Full Text] [Related]
35. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Harden SV; Tokumaru Y; Westra WH; Goodman S; Ahrendt SA; Yang SC; Sidransky D Clin Cancer Res; 2003 Apr; 9(4):1370-5. PubMed ID: 12684406 [TBL] [Abstract][Full Text] [Related]
37. Aberrant promoter hypermethylation of selected apoptotic genes in childhood acute lymphoblastic leukemia among North Indian population. Nikbakht M; Jha AK; Malekzadeh K; Askari M; Mohammadi S; Marwaha RK; Kaul D; Kaur J Exp Oncol; 2017 Mar; 39(1):57-64. PubMed ID: 28361856 [TBL] [Abstract][Full Text] [Related]
38. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review. Yu Q; Guo Q; Chen L; Liu S Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811 [TBL] [Abstract][Full Text] [Related]
39. [The role of lung cancer related gene methylation in the early diagnosis of lung cancer]. Li Y; Fan QX Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):644-647. PubMed ID: 32867455 [No Abstract] [Full Text] [Related]
40. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Vallböhmer D; Brabender J; Yang D; Schneider PM; Metzger R; Danenberg KD; Hölscher AH; Danenberg PV Clin Lung Cancer; 2006 Jul; 8(1):39-44. PubMed ID: 16870044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]